Publicação
Conservative Care Management in Chronic Kidney Disease: A Value for the Money?
| Resumo: | Abstract End stage kidney disease (ESKD) is a potentially fatal disease that can be treated by one of three modalities: dialysis (hemodialysis or peritoneal dialysis) and kidney transplantation. Either of these options represents a heavy burden on health systems. Kidney transplantation has its own financial framework. Dialysis care, provided by public or private institutions is funded, since 2008, by a prospective bundle payment system called preço compreensivo (“comprehensive price”). In 2011, Direção Geral de Saúde (Directorate General of Health) proposed in “Norma 17” a fourth modality to handle ESKD: conservative care management (or kidney palliative care). This option focuses treatments on improving quality of life (and in some cases, time) in frail patients or patients who opt not to proceed to invasive treatment options. “Norma 17” regulated the clinical framework for this proposal but its socioeconomic evaluation and subsequent reimbursement has not been established. This has become a barrier to its application by public and private providers. This work intends to reflect the individual, social and economic benefits of the implementation of the conservative care option so healthcare decision makers may support their decisions. The authors reflect on the limitations to analyze costs and results in end ‑of ‑life care and propose outcomes to compare dialysis and conservative care in ESKD. |
|---|---|
| Autores principais: | Farinha,Ana |
| Outros Autores: | Coelho,Pedro Barata; Rodrigues,António Teixeira |
| Assunto: | Cost of Illness Health Care Costs Kidney Failure, Chronic/economics Renal Insufficiency, Chronic/economics |
| Ano: | 2024 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Fundação para a Ciência e Tecnologia |
| Idioma: | inglês |
| Origem: | SciELO Portugal |
| Resumo: | Abstract End stage kidney disease (ESKD) is a potentially fatal disease that can be treated by one of three modalities: dialysis (hemodialysis or peritoneal dialysis) and kidney transplantation. Either of these options represents a heavy burden on health systems. Kidney transplantation has its own financial framework. Dialysis care, provided by public or private institutions is funded, since 2008, by a prospective bundle payment system called preço compreensivo (“comprehensive price”). In 2011, Direção Geral de Saúde (Directorate General of Health) proposed in “Norma 17” a fourth modality to handle ESKD: conservative care management (or kidney palliative care). This option focuses treatments on improving quality of life (and in some cases, time) in frail patients or patients who opt not to proceed to invasive treatment options. “Norma 17” regulated the clinical framework for this proposal but its socioeconomic evaluation and subsequent reimbursement has not been established. This has become a barrier to its application by public and private providers. This work intends to reflect the individual, social and economic benefits of the implementation of the conservative care option so healthcare decision makers may support their decisions. The authors reflect on the limitations to analyze costs and results in end ‑of ‑life care and propose outcomes to compare dialysis and conservative care in ESKD. |
|---|